Parkinsonian Disorders

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Ancona, Italy
• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Brescia, Italy
• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Catania, Italy
• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Genova, Italy

Not specified

• Phase I Unit, Orion Pharma — Espoo, Finland

• USF Parkinson's Disease and Movement Disorders Center — Tampa, Florida, United States

• Westmead Hospital — Sydney, New South Wales, Australia
• The Royal Brisbane and Women's Hospital — Brisbane, Queensland, Australia
• Austin Hospital — Melbourne, Victoria, Australia
• Dunedin Hospital — Dunedin, Otago, New Zealand

• Hadassah Medical Organization — Jerusalem, Israel

• University of Rochester — Rochester, New York, United States

• Novartis Investigator Site — Dresden, Germany
• Novartis Investigator Site — Kassel, Germany
• Novartis Investigator Site — Leun, Germany
• Novartis Investigator Site — Marburg, Germany

• Centre d'Investigation Clinique, Hôpital de la Pitié-Salpétrière, — Paris, France

Not specified